Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Jemperli (dostarlimab) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Jemperli is the only immuno-oncology treatment approved in a frontline setting for this patient population in combination with chemotherapy
-
Strong performance and momentum drive upgraded guidance
Q2 2023 performance highlights
-
ViiV Healthcare’s cabotegravir for HIV prevention receives positive CHMP opinion from European Medicines Agency
Cabotegravir is the first and only long-acting injectable option for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1
-
New analysis shows lost ground on adult immunisation during the pandemic with 100 million doses potentially missed
Despite successes in Covid-19 vaccination programmes, global uptake of some other adult vaccines fell during the same timeframe
-
Medicines and Healthcare products Regulatory Agency authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Authorisation will help protect adults 60 years of age and older in the UK from RSV disease for the first time
-
GSK completes acquisition of BELLUS Health
BELLUS is a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough.
-
GSK receives US FDA Fast Track designation for investigational vaccine against gonorrhoea
Fast Track designation accelerates the vaccine candidate’s path to US FDA submission for the prevention of Neisseria gonorrhoeae infection
-
Japan’s Ministry of Health, Labour and Welfare approves Shingrix for the prevention of shingles in at-risk adults aged 18 and over
Approval expands the number of people who can be protected against shingles.
-
GSK receives positive CHMP opinion recommending authorisation of daprodustat for symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis
The positive CHMP opinion is based on data from three global phase III trials in dialysis patients from the ASCEND clinical trial programme.
-
Statement - Zantac (ranitidine) litigation
GSK today confirmed it has reached a confidential settlement with James Goetz.
-
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend Arexvy for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
Committee recommendations mean over 55 million older adults in the US could have access to RSV vaccination for the first time
-
GSK shares positive data for Arexvy, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
Results from the ongoing AReSVi-006 phase III trial show vaccine efficacy over two full seasons
-
GSK announces extension of FDA review period for momelotinib
GSK is confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review.
-
European Commission authorises GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for older adults
Authorisation will help protect adults 60 years of age and older in 30 European countries from RSV disease for the first time
-
GSK receives US FDA file acceptance for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer
Submission accepted for Priority Review
-
GSK presents pivotal data at ESPID confirming effectiveness of its 5-in-1 meningococcal ABCWY vaccine candidate, with demonstrated coverage against a panel of 110 MenB strains
GSK today presented preliminary positive results from the phase III trial
-
Statement: Zantac (ranitidine) litigation
GSK welcomes the decision of the British Columbia Supreme Court in Dussiaume v. Sandoz Canada Inc. 2023 BCSC 795
-
US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
-
GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion
Positive opinion advances GSK’s goal to provide the first vaccine to help protect older adults from respiratory syncytial virus disease
-
GSK momentum continues with strong start to 2023
Q1 2023 performance highlights
